Biotech, Digital Health, Medical Device, Personalised medicine, Therapeutics, EMR / EHR, medical big data and analytics, mobile fitness / health apps
I am CEO of a digital therapeutic in skincare based in the USA. Our company uses an app equipped with our very own technology that allows us adapt each user’s treatment journey, weekly. We make assessments of progress with computer vision and AI, then coach users to modify their treatment routines and supply the appropriate products for those routines.
My previous role was VP of marketing at Curelator / N1 Headache, a digital therapeutic for migraine. It has a clinical facing web platform with EHR integrations and an patient-facing that collects data through a very engaging diary that is able to find out correlation of lifestyle factors with migraine, an approach that has been tested in clinical trials and allows for lifestyle therapeutic interventions.
The data collected also has great relevant in clinical settings for population analyses (like this https://pubmed.ncbi.nlm.nih.gov/30334248/), so I am very familiar with EMR/EHR hurdles in the USA and big dataset statistics.
Most of my career has been related to the pharmaceutical world in marketing, and business development positions. During my tenure in Almirall, I co-led teams that made relevant decisions to the R&D and commercial portfolios across multiple therapeutic areas: oncology, autoimmune, gastrointestinal. I led the launch of a first in class therapeutic for IBS, a very neglected area that had many reimbursement hurdles in all countries under my supervision (EU + Mexico).
Daniel Oliver directly